Compare FMC Corp (FMC) vs TG Therapeutics Inc (TGTX) Price & Performance

FMC Corporation (FMC) trades at $10.24, down 2.1% today, reflecting ongoing investor concerns despite recent earnings beats. The stock shows a bearish technical signal with key support at $10 and resistance at $11. Fundamentally, the company faces significant challenges with a net income margin of -84.83% and negative ROE of -91.47% for 2025, though valuation ratios like P/S of 0.4 and P/B of 0.8 appear attractive. Recent developments include a $400 million minority investment from Tessenderlo Group and regulatory submission for new herbicide technology.

The outlook remains cautious due to persistent profitability issues and revenue declines, with 2025 revenue dropping to $3.47B from $4.2B in 2024. While analyst consensus is mixed with a $11.60 price target suggesting modest upside, high debt levels and competitive pressures pose substantial risks. The company's focus on debt reduction through asset sales and external investments provides some stability, but turnaround execution is critical for sustained recovery.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.